BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 17, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Norovirus VLP vaccine: Phase I data

Data from the double-blind, dose-escalation, U.S. Phase I LV01-101 trial in 28 healthy volunteers ages 18-49 showed that 5, 15 and 50 µg doses of intranasal Norovirus VLP vaccine produced seroconversion rates, defined as the proportion of...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >